Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lindy Vernooij"'
Autor:
Lindy Vernooij, Alvin Kamili, Kimberley Ober, Jennemiek van Arkel, Lina Lankhorst, Enya Vermeulen, Hanin Al-Khakany, Gabor Tax, Marlinde L. van den Boogaard, Jamie I. Fletcher, Selma Eising, Jan J. Molenaar, M. Emmy M. Dolman
Publikováno v:
EJC Paediatric Oncology, Vol 3, Iss , Pp 100168- (2024)
Background: Neuroblastoma is the most common extracranial pediatric solid malignancy with high-risk patients showing survival rates less than 50 %. These tumors frequently escape apoptosis through upregulation of the anti-apoptotic protein BCL-2. Unf
Externí odkaz:
https://doaj.org/article/248810243e214da890e1924fb4d60647
Autor:
Thomas F. Eleveld, Lindy Vernooij, Linda Schild, Bianca Koopmans, Lindy K. Alles, Marli E. Ebus, Rana Dandis, Harm van Tinteren, Huib N. Caron, Jan Koster, Max M. van Noesel, Godelieve A. M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating th
Externí odkaz:
https://doaj.org/article/f113f91a5d74419a8ac27a8cd36776b9
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Supplementary data including supplementary figures S1 to S6 and supplementary tables S1 to S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c19a6188349cc1e7ae304543adf5a25
https://doi.org/10.1158/1535-7163.22522524
https://doi.org/10.1158/1535-7163.22522524
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Supplementary information on the used materials and methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737308f3d4a0e5a27d921f6744ac9ebf
https://doi.org/10.1158/1535-7163.22522521.v1
https://doi.org/10.1158/1535-7163.22522521.v1
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Neuroblastoma tumors frequently overexpress the anti-apoptotic protein B-cell lymphoma/leukemia 2 (BCL-2). We previously showed that treating BCL-2–dependent neuroblastoma cells with the BCL-2 inhibitor venetoclax results in apoptosis, but unfortun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94290ce21ef15de16b10560ee4307a2
https://doi.org/10.1158/1535-7163.c.6543414.v1
https://doi.org/10.1158/1535-7163.c.6543414.v1
Autor:
Thomas F. Eleveld, Lindy Vernooij, Linda Schild, Bianca Koopmans, Lindy K. Alles, Marli E. Ebus, Rana Dandis, Harm van Tinteren, Huib N. Caron, Jan Koster, Max M. van Noesel, Godelieve A. M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar
Publikováno v:
SSRN Electronic Journal.
IntroductionMutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating th
Autor:
Bianca Koopmans, Thomas F. Eleveld, Lindy Vernooij, Rogier Versteeg, Emmy Dolman, Huib N. Caron, Marli E. Ebus, Jan Koster, Lindy K. Alles, Peter van Sluis, Linda Schild, Jan J. Molenaar
Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating the need for c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a149c61ba3deceda7fd2cabb881ad8a7
https://doi.org/10.1101/2020.02.12.945089
https://doi.org/10.1101/2020.02.12.945089
Autor:
Marlinde L. van den Boogaard, Emmy Dolman, Nil A. Schubert, Jan J. Molenaar, Lindy K. Alles, Stijn van Oirschot, Lindy Vernooij, Marloes E. Nulle, Linda Schild, Kaylee M. Keller
Publikováno v:
Cancer Research. 80:A49-A49
Neuroblastomas account for approximately 15% of all childhood cancer deaths. Clinical complete remission is achieved in many stage 4 neuroblastoma patients, but the high risk of relapse and the accompanying treatment-resistant nature of these tumors
Autor:
Bianca Koopmans, Lindy Vernooij, Laurel T. Bate-Eya, Jan J. Molenaar, M. Emmy M. Dolman, Ronald W. Stam, Daphne Lelieveld, Mark Kerstjens, Anke H. W. Essing, Huib N. Caron, David A. Egan, Lindy K. Alles
Publikováno v:
Cancer Research. 78:2630-2630
BACKGROUND: The anti-apoptotic protein B cell lymphoma/leukaemia 2 (BCL-2) is highly expressed in the majority of all neuroblastomas. In previous preclinical studies, we have shown that treatment of BCL-2-dependent neuroblastoma with BCL-2 inhibitors